Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels
Objective: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR: : ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCR: : ABL...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2022-08-01
|
| Series: | Turkish Journal of Hematology |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-93609 |
| _version_ | 1797921782090432512 |
|---|---|
| author | Funda Ceran Sema Akıncı Mehmet Ali Uçar Gülten Korkmaz Mehmet Gündüz Büşranur Çavdarlı Şule Mine Bakanay Mesude Falay Simten Dağdaş İmdat Dilek Gülsüm Özet |
| author_facet | Funda Ceran Sema Akıncı Mehmet Ali Uçar Gülten Korkmaz Mehmet Gündüz Büşranur Çavdarlı Şule Mine Bakanay Mesude Falay Simten Dağdaş İmdat Dilek Gülsüm Özet |
| author_sort | Funda Ceran |
| collection | DOAJ |
| description | Objective: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR: : ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCR: : ABL1 International Scale (IS). We aimed to investigate the prognostic role of BCR: : ABL1 transcript levels, HT, and RR on molecular response kinetics at 3 months in patients with newly diagnosed chronic-phase (CP)-CML. Materials and Methods: Forty patients with CP-CML who received first-line imatinib treatment were included in this study. BCR: : ABL1 transcript levels and molecular responses at baseline and at 3, 6, 12, and 24 months of treatment were evaluated retrospectively. Major molecular response (MMR) at 12 months and event-free survival (EFS) were determined as primary endpoints and the effects of treatment kinetics on these parameters were examined. Results: Of the 40 patients, BCR: : ABL1 IS was ≤10% at 3 months in 72.5%, representing EMR. The rate of event occurrence was 45.5% in patients with BCR: : ABL1 IS of >10%, whereas it was 6.9% in those with BCR: : ABL1 IS of ≤10% (p=0.004). MMR was detected in 62.1% of the patients with EMR and in 9.1% of those without EMR (p=0.003). The cut-off value for achieving MMR was 24 days for HT and 0.04 for RR. Deep molecular response (DMR) at 24 months was associated with HT of ≤24 days and RR of ≤0.04. EFS was found to be significantly better in the group with BCR: : ABL1 IS of ≤10% and HT of ≤24 days (p=0.001) and in the group with BCR: : ABL1 IS of ≤10% and RR of ≤0.04 (p=0.007) compared to others. Conclusion: Our findings revealed that MMR could be predicted via EMR as well as by HT and RR. Additionally, HT of ≤24 days and RR of ≤0.04 were more important than BCR: : ABL1 IS of ≤10% in achieving DMR at 24 months, and the combination of BCR: : ABL1 IS of ≤10% with both HT of ≤24 days and RR of ≤0.04 has the best predictive value for EFS. |
| first_indexed | 2024-04-10T14:22:05Z |
| format | Article |
| id | doaj.art-9ada105c49da47f79198c8ab6db559d5 |
| institution | Directory Open Access Journal |
| issn | 1308-5263 |
| language | English |
| last_indexed | 2024-04-10T14:22:05Z |
| publishDate | 2022-08-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkish Journal of Hematology |
| spelling | doaj.art-9ada105c49da47f79198c8ab6db559d52023-02-15T16:09:17ZengGalenos Publishing HouseTurkish Journal of Hematology1308-52632022-08-0139319620310.4274/tjh.galenos.2022.2022-0024TJH-93609Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript LevelsFunda Ceran0Sema Akıncı1Mehmet Ali Uçar2Gülten Korkmaz3Mehmet Gündüz4Büşranur Çavdarlı5Şule Mine Bakanay6Mesude Falay7Simten Dağdaş8İmdat Dilek9Gülsüm Özet10Ankara City Hospital, Clinic of Hematology, Ankara, TurkeyAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyÇukurova University Faculty of Medicine, Department of Hematology, Ankara, TurkeyAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyBiruni University Faculty of Medicine, Department of Hematology, İstanbul, TurkeyAnkara City Hospital, Clinic of Medical Genetics, Ankara, TurkeyAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyDüzen Laboratory Group, Department of Biochemistry, Ankara, TurkeyAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyAnkara City Hospital, Clinic of Hematology, Ankara, TurkeyObjective: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR: : ABL1 transcript levels have recently emerged as additional prognostic indexes besides the BCR: : ABL1 International Scale (IS). We aimed to investigate the prognostic role of BCR: : ABL1 transcript levels, HT, and RR on molecular response kinetics at 3 months in patients with newly diagnosed chronic-phase (CP)-CML. Materials and Methods: Forty patients with CP-CML who received first-line imatinib treatment were included in this study. BCR: : ABL1 transcript levels and molecular responses at baseline and at 3, 6, 12, and 24 months of treatment were evaluated retrospectively. Major molecular response (MMR) at 12 months and event-free survival (EFS) were determined as primary endpoints and the effects of treatment kinetics on these parameters were examined. Results: Of the 40 patients, BCR: : ABL1 IS was ≤10% at 3 months in 72.5%, representing EMR. The rate of event occurrence was 45.5% in patients with BCR: : ABL1 IS of >10%, whereas it was 6.9% in those with BCR: : ABL1 IS of ≤10% (p=0.004). MMR was detected in 62.1% of the patients with EMR and in 9.1% of those without EMR (p=0.003). The cut-off value for achieving MMR was 24 days for HT and 0.04 for RR. Deep molecular response (DMR) at 24 months was associated with HT of ≤24 days and RR of ≤0.04. EFS was found to be significantly better in the group with BCR: : ABL1 IS of ≤10% and HT of ≤24 days (p=0.001) and in the group with BCR: : ABL1 IS of ≤10% and RR of ≤0.04 (p=0.007) compared to others. Conclusion: Our findings revealed that MMR could be predicted via EMR as well as by HT and RR. Additionally, HT of ≤24 days and RR of ≤0.04 were more important than BCR: : ABL1 IS of ≤10% in achieving DMR at 24 months, and the combination of BCR: : ABL1 IS of ≤10% with both HT of ≤24 days and RR of ≤0.04 has the best predictive value for EFS.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-93609chronic myeloid leukemiabcr: : abl1 ishalving timereduction ratiomolecular response |
| spellingShingle | Funda Ceran Sema Akıncı Mehmet Ali Uçar Gülten Korkmaz Mehmet Gündüz Büşranur Çavdarlı Şule Mine Bakanay Mesude Falay Simten Dağdaş İmdat Dilek Gülsüm Özet Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels Turkish Journal of Hematology chronic myeloid leukemia bcr: : abl1 is halving time reduction ratio molecular response |
| title | Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels |
| title_full | Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels |
| title_fullStr | Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels |
| title_full_unstemmed | Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels |
| title_short | Leukemia: Reduction Ratio and Halving Time of BCR: : ABL1 IS Transcript Levels |
| title_sort | leukemia reduction ratio and halving time of bcr abl1 is transcript levels |
| topic | chronic myeloid leukemia bcr: : abl1 is halving time reduction ratio molecular response |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-93609 |
| work_keys_str_mv | AT fundaceran leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT semaakıncı leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT mehmetaliucar leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT gultenkorkmaz leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT mehmetgunduz leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT busranurcavdarlı leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT suleminebakanay leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT mesudefalay leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT simtendagdas leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT imdatdilek leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels AT gulsumozet leukemiareductionratioandhalvingtimeofbcrabl1istranscriptlevels |